Galapagos NV (GLPG)

GLPG JAK Fibrosis Inflammation

BiotechSign Signal Grade

Signal Grade

7.2/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying

Publications

100

Dilution Risk

Clinical Activity

Short Interest

Pipeline Overview

Therapeutic Focus: JAK Fibrosis Inflammationsrc

Clinical Trial Activity

Clinical Trials
(ClinicalTrials.gov aggregate)

PubMed Publications

Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov

Dilution Risk

MEDIUM DILUTION RISK

36/100

Dilution Score

40Warrant Risk

40Convertible Risk

40Offering Ability

Dilution score: 36/100 (MEDIUM), cash runway not available

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

3.22%

Float Shorted

11.2

Days to Cover

MODERATE

Squeeze Risk

+4.7%

SI Change

STABLE

Trend

1,435,699

Shares Short

Short interest: 3.22% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Recent Publications

Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses. — J Crohns Colitis 2026 Sep 3 Giorio L PMID 42728025
Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years. — Mult Scler Relat Disord 2026 Oct Olsson T PMID 42561748
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. — J Clin Oncol 2026 Aug 10 Eyre TA PMID 42385124
Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL. — Blood Adv 2026 Sep 8 Crombie JL PMID 42335220
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results. — J Crohns Colitis 2026 Jun 7 Jairath V PMID 42309525

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Galapagos NV.

Full GLPG Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.